NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Nice example. Thanks. Let me suggest just a slightly different emphasis/conclusion regarding the present value for this prior case study. Eloxatin was used as an adjuvant -- as opposed to replacing standard of care. Still, while the therapy did not replace the standard of care (only added to it), your example is one more arrow in the quiver to demonstrate independent 'clinical' value for disease free progression, and therefore, progression free survival. Likewise, while we hope for S.O.C status for Direct, as Linda states, 'THERE IS NO STANDARD OF CARE FOR THE PATIENTS CURRENTLY BEING TREATED WITH DCVAX-DIRECT.' Thus, Direct can be thought of, for analogy purposes only (don't take me too literally), as an adjuvant to earlier in time treatments -- when we are speaking about inoperable cancer. (Of course, in reality, Direct is/will be a stand alone treatment for what were previously untreatable diseases.)